

ASX RELEASE

Appointment of Chief Financial Officer and Joint Company Secretary

Wellington, NZ, 2 March 2017: Volpara Health Technologies Limited (ASX: VHT) announced today the appointment of Craig Hadfield to the position of Chief Financial Officer (CFO) and Joint Company Secretary. Mr. Hadfield, replaces Brian Leighs who has served as a contract CFO at Volpara, since 2009.

Mr. Hadfield brings over eight years' experience in senior and managerial auditing roles at large accounting firms including EY and Deloitte. He was most recently an Associate Director for Deloitte Wellington and was the Audit Manager for VHT during the IPO process. Previously, he held roles internationally, including in the US, South Africa, New Zealand, and Bahamas. Mr. Hadfield holds an Honours Degree in Accounting from the University of Witwatersrand (Johannesburg, South Africa) and is a Qualified Chartered Accountant registered with the South African Institute of Chartered Accountants (SAICA), and is an Affiliate of NZICA (CAANZ).

Dr Ralph Highnam, CEO of Volpara said "I am delighted to congratulate Craig on his elevation to the role of full-time CFO, and thank Brian for his immense contribution to the company. Bringing on a full-time CFO, strengthens our management team during this important phase in our growth. Craig will play an important role in implementing our growth strategy, and also ensuring the company continues to enforce tighter financial controls across all business units."

Mr. Hadfield has been performing the role of Financial Controller at Volpara for the past six months. John F Diddams, who is also a non-executive Director of the company, remains in the role of Joint Company Secretary, now alongside Mr Hadfield.

ENDS

About Volpara Health Technologies Limited (ASX: VHT)

Founded in 2009 from research originally conducted at Oxford University, VHT is based in Wellington, New Zealand and facilitates the early detection of breast cancer through its digital health solutions to enable personalised, high-quality breast cancer screening based on automated, objective measurements of breast density and quality.

VHT has a number of patents and trademarks and regulatory clearances, including FDA and CE, supporting its technology and services.

VHT, an ASX-listed company that raised A\$20M through an IPO and subsequent share placement and rights issue in 2016, has customers and/or research projects in 35 countries.

www.volparasolutions.com

For further information, please contact:

Ralph Highnam, CEO
Volpara Health Technologies
ralph.highnam@volparasolutions.com
t: +64 21 149 0541

Kyahn Williamson
WE Buchan
kwilliamson@buchanwe.com.au
t: +61 3 9866 4722